Facing cancer takes courage. clonoSEQ helps doctors detect, quantify, and monitor small amounts of cancer known as measurable (or minimal) residual disease (MRD) to inform treatment throughout a …

Adaptive must have a valid Clonality (ID) Test result in order to generate a Tracking (MRD) Test result for a given patient. Delivery of clinical reports containing MRD results will be delayed until a …

Detect, quantify, and assess cancer cells that may remain in the body to get the most of of today's advanced therapies. Learn more about clonoSEQ.

The clonoSEQ Assay is a laboratory service performed at Adaptive Biotechnologies' single site located at 1551 Eastlake Ave E, Seattle, WA 98102. This test was developed and its performance …

In the event that coverage for clonoSEQ is limited or denied, Adaptive will help appeal the claim when possible and work on behalf of the patient to seek payment for clonoSEQ testing services.

Access and download important information about the benefits of clonoSEQ to patients, how to order, specimen and pathology requirements and a technical summary.

As blood cancer fluctuates, monitoring with clonoSEQ provides enhanced clarity into the status of MRD. Test at multiple timepoints across your patient’s journey to measure the effectiveness of treatment …

Adaptive Biotechnologies Corporation announced today new data highlighting the clinical utility of Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual …

Built on the foundational innovations of Adaptive Biotechnologies’ proprietary immunosequencing platform, the clonoSEQ ® Assay is designed to address these needs.

Relapse after initial remission is common in ALL. Test regularly with clonoSEQ to measure deep repsonses and detect potential relapse earlier.